Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.

about

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.

Item

http://www.wikidata.org/entity/Q50569337

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Human equilibrative nucleoside ...... iomyosarcoma and angiosarcoma.

@en

Human equilibrative nucleoside ...... iomyosarcoma and angiosarcoma.

@nl

type

Item

label

Human equilibrative nucleoside ...... iomyosarcoma and angiosarcoma.

@en

Human equilibrative nucleoside ...... iomyosarcoma and angiosarcoma.

@nl

prefLabel

Human equilibrative nucleoside ...... iomyosarcoma and angiosarcoma.

@en

Human equilibrative nucleoside ...... iomyosarcoma and angiosarcoma.

@nl

P1476

Human equilibrative nucleoside ...... iomyosarcoma and angiosarcoma.

@en

P2093

Andrea Onetti Muda

http://www.w3.org/2001/XMLSchema#string

Bruno Vincenzi

http://www.w3.org/2001/XMLSchema#string

Carla Rabitti

http://www.w3.org/2001/XMLSchema#string

Francesco Pantano

http://www.w3.org/2001/XMLSchema#string

Giuseppe Badalamenti

http://www.w3.org/2001/XMLSchema#string

Giuseppe Perrone

http://www.w3.org/2001/XMLSchema#string

Giuseppe Tonini

http://www.w3.org/2001/XMLSchema#string

Michele Iuliani

http://www.w3.org/2001/XMLSchema#string

Paola Collini

http://www.w3.org/2001/XMLSchema#string

Paolo Casali

http://www.w3.org/2001/XMLSchema#string

P2860

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells

Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes.

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?

Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

P2888

bjc.2017.187

P304

340-346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2017.187

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28641307

http://www.w3.org/2001/XMLSchema#string

P932

5537497

http://www.w3.org/2001/XMLSchema#string